PREDICTIVE VALUE OF INTEGRATING CIRCULATING TUMOR DNA AND END-OF-TREATMENT PET/CT FOR RELAPSE PREDICTION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED AT A REFERRAL CENTER
4 affiliations
- 1Centro de Hematologia e Hemoterapia (Hemocentro), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brasil
- 2Fleury Medicina e Saúde, São Paulo, SP, Brasil
- 3Instituto de Física Gleb Wataghin, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brasil
- 4Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brasil
Abstract
Background: Diffuse large B-Cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). End-of-treatment (EOT) FDG-PET/CT is the standard imaging modality for response assessment in diffuse large B-cell lymphoma (DLBCL); however, its ability to accurately identify patients at risk of relapse remains limited. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for disease burden, treatment response, and detection of molecular residual disease. Aim: To evaluate the correlation between ctDNA levels before and at the end of treatment in patients diagnosed with DLBCL, as well as their association with response assessment by PET/CT. Materials and methods: Newly diagnosed patients with DLBCL treated at our institution between October 2018 and November 2021 were included. All patients provided written informed consent to participate in the study. Blood samples for plasma ctDNA analysis were collected before treatment (ctDNA1) in dedicated DNA-stabilizing blood collection tubes. Patients underwent chemoimmunotherapy, and eight weeks after treatment completion, a second peripheral blood sample was collected for ctDNA analysis (ctDNA2). Disease staging and treatment response assessment were performed using FDG-PET/CT. At the end of treatment, patients were categorized into four groups: 1) PET/CT-negative / ctDNA2-negative; 2) PET/CT-negative / ctDNA2-positive; 3) PET/CT-positive / ctDNA2-negative; and 4) PET/CT-positive / ctDNA2-positive. Results: Eighteen patients were included in the study, with a median age at diagnosis of 59 years and a female predominance (55.6%). Overall, 36.4% had localized disease (stage I/II) and 63.6% had advanced-stage disease (stage IV). Regarding cell of origin, according to the Hans algorithm, 38.9% and 44.4% were classified as germinal center B-cell–like (GCB) and activated B-cell–like (ABC), respectively. Following first-line treatment, 83% of patients achieved a complete response, whereas 11% had primary refractory disease. With a median follow-up of 58 months, one patient experienced relapse after 13 months. At the end of the observation period, seven patients (38%) had died; among them, two had relapsed disease, whereas five were in remission and died from causes unrelated to lymphoma. Among the evaluated groups, a statistically significant difference was observed in both progression-free survival and overall survival curves (p < 0.001), with the best outcomes observed in group 2, followed by group 1, and the worst outcomes in group 4. Conclusion: The combined use of PET/CT and ctDNA may represent a useful tool for the assessment of patients with DLBCL. These findings highlight the importance of further studies evaluating longitudinal ctDNA dynamics during follow-up in patients who achieve a complete response, with the aim of better defining its role as a prognostic biomarker.
Related
- High Frequency of Circulating IL-4R+SELL+ Naïve B Cells Is Associated with Functional Cure in Chronic Hepatitis B Patients Receiving Antiviral Treatment
- Early Assessment of Circulating Tumor Cells and Their PD-L1 Expression as Predictive Biomarkers in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: An Exploratory Study
- Development and validation of a fall risk prediction model integrating objective gait metrics for patients with cerebral small vessel disease: protocol for a two-phase study
- A genetic algorithm–optimized EWMA control chart integrating machine learning-based risk prediction for multistage thyroid cancer treatment monitoring
- Pretreatment prediction of early severe treatment-related toxicity in older patients with lung adenocarcinoma: same-center temporal validation of a risk model
BibTeX
@article{cralcev2026predictive,
title = {{PREDICTIVE VALUE OF INTEGRATING CIRCULATING TUMOR DNA AND END-OF-TREATMENT PET/CT FOR RELAPSE PREDICTION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED AT A REFERRAL CENTER}},
author = {Christopher CRALCEV and Guilherme DUFFLES and Jersey Heitor Silva MAUÉS and Fernanda LUPINACCI and Luciana GUILHERMINO PEREIRA and Elisa NAPOLITANO FERREIRA and Fernanda SOARES NIEMANN and Maria Emilia SEREN TAKAHASHI and Celso DARÍO RAMOS and Maria Lourdes L. FERRARI CHAUFFAILLE and Irene LORAND-METZE},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2026},
month = oct,
doi = {10.1016/j.htct.2026.107811},
url = {https://doi.org/10.1016/j.htct.2026.107811},
note = {CC BY},
}
RIS
TY - JOUR
TI - PREDICTIVE VALUE OF INTEGRATING CIRCULATING TUMOR DNA AND END-OF-TREATMENT PET/CT FOR RELAPSE PREDICTION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED AT A REFERRAL CENTER
AU - Christopher CRALCEV
AU - Guilherme DUFFLES
AU - Jersey Heitor Silva MAUÉS
AU - Fernanda LUPINACCI
AU - Luciana GUILHERMINO PEREIRA
AU - Elisa NAPOLITANO FERREIRA
AU - Fernanda SOARES NIEMANN
AU - Maria Emilia SEREN TAKAHASHI
AU - Celso DARÍO RAMOS
AU - Maria Lourdes L. FERRARI CHAUFFAILLE
AU - Irene LORAND-METZE
PY - 2026
DA - 2026/10/23
JO - Hematology, Transfusion and Cell Therapy
DO - 10.1016/j.htct.2026.107811
UR - https://doi.org/10.1016/j.htct.2026.107811
AB - Background: Diffuse large B-Cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). End-of-treatment (EOT) FDG-PET/CT is the standard imaging modality for response assessment in diffuse large B-cell lymphoma (DLBCL); however, its ability to accurately identify patients at risk of relapse remains limited. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for disease burden, treatment response, and detection of molecular residual disease. Aim: To evaluate the correlation between ctDNA levels before and at the end of treatment in patients diagnosed with DLBCL, as well as their association with response assessment by PET/CT. Materials and methods: Newly diagnosed patients with DLBCL treated at our institution between October 2018 and November 2021 were included. All patients provided written informed consent to participate in the study. Blood samples for plasma ctDNA analysis were collected before treatment (ctDNA1) in dedicated DNA-stabilizing blood collection tubes. Patients underwent chemoimmunotherapy, and eight weeks after treatment completion, a second peripheral blood sample was collected for ctDNA analysis (ctDNA2). Disease staging and treatment response assessment were performed using FDG-PET/CT. At the end of treatment, patients were categorized into four groups: 1) PET/CT-negative / ctDNA2-negative; 2) PET/CT-negative / ctDNA2-positive; 3) PET/CT-positive / ctDNA2-negative; and 4) PET/CT-positive / ctDNA2-positive. Results: Eighteen patients were included in the study, with a median age at diagnosis of 59 years and a female predominance (55.6%). Overall, 36.4% had localized disease (stage I/II) and 63.6% had advanced-stage disease (stage IV). Regarding cell of origin, according to the Hans algorithm, 38.9% and 44.4% were classified as germinal center B-cell–like (GCB) and activated B-cell–like (ABC), respectively. Following first-line treatment, 83% of patients achieved a complete response, whereas 11% had primary refractory disease. With a median follow-up of 58 months, one patient experienced relapse after 13 months. At the end of the observation period, seven patients (38%) had died; among them, two had relapsed disease, whereas five were in remission and died from causes unrelated to lymphoma. Among the evaluated groups, a statistically significant difference was observed in both progression-free survival and overall survival curves (p < 0.001), with the best outcomes observed in group 2, followed by group 1, and the worst outcomes in group 4. Conclusion: The combined use of PET/CT and ctDNA may represent a useful tool for the assessment of patients with DLBCL. These findings highlight the importance of further studies evaluating longitudinal ctDNA dynamics during follow-up in patients who achieve a complete response, with the aim of better defining its role as a prognostic biomarker.
SN - 2531-1379
SN - 2531-1387
ER -